WO2001057245A3 - Hiv-1 resistance assay - Google Patents

Hiv-1 resistance assay Download PDF

Info

Publication number
WO2001057245A3
WO2001057245A3 PCT/BE2001/000017 BE0100017W WO0157245A3 WO 2001057245 A3 WO2001057245 A3 WO 2001057245A3 BE 0100017 W BE0100017 W BE 0100017W WO 0157245 A3 WO0157245 A3 WO 0157245A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
genes
involves
resistance
env
Prior art date
Application number
PCT/BE2001/000017
Other languages
French (fr)
Other versions
WO2001057245A2 (en
Inventor
Myriam Witvrouw
Valery Fikkert
Christophe Pannecouque
Peter Cherepanov
Laethem Kristel Van
Clercq Erik De
Anne-Mieke Vandamme
Zeger Debyser
Original Assignee
Leuven K U Res & Dev
Myriam Witvrouw
Valery Fikkert
Christophe Pannecouque
Peter Cherepanov
Laethem Kristel Van
Clercq Erik De
Anne-Mieke Vandamme
Zeger Debyser
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0002533A external-priority patent/GB0002533D0/en
Priority claimed from GB0101011A external-priority patent/GB0101011D0/en
Application filed by Leuven K U Res & Dev, Myriam Witvrouw, Valery Fikkert, Christophe Pannecouque, Peter Cherepanov, Laethem Kristel Van, Clercq Erik De, Anne-Mieke Vandamme, Zeger Debyser filed Critical Leuven K U Res & Dev
Priority to AU2001233513A priority Critical patent/AU2001233513A1/en
Publication of WO2001057245A2 publication Critical patent/WO2001057245A2/en
Publication of WO2001057245A3 publication Critical patent/WO2001057245A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Present invention involves a recombination assay for the HIV envelope genes, gp120, gp41, and gp160. It further involves env-deleted proviral clones, the optimization of the PCR amplification of the corresponding env-genes and the subsequent sequencing of these genes. These techniques have been applied on several HIV-1(NL4.3) strains selected in vitro in the presence of increasing concentrations of inhibitors of HIV entry and evaluated for the phenotypic resistance of these recombined viruses. This phenotypic resistance has been correlated with genotypic resistance. Present invention also involves a recombination assay for the integrase gene.
PCT/BE2001/000017 2000-02-04 2001-02-05 Hiv-1 resistance assay WO2001057245A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001233513A AU2001233513A1 (en) 2000-02-04 2001-02-05 Hiv-1 resistance assay

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0002533.8 2000-02-04
GB0002533A GB0002533D0 (en) 2000-02-04 2000-02-04 Recombination virus assays used for the elucidation of the molecular of action of antiviral drugs & the determination of reistance of clinical virus isolates
GB0101011.5 2001-01-15
GB0101011A GB0101011D0 (en) 2001-01-15 2001-01-15 Evaluation of HIV-1 resistance

Publications (2)

Publication Number Publication Date
WO2001057245A2 WO2001057245A2 (en) 2001-08-09
WO2001057245A3 true WO2001057245A3 (en) 2002-06-27

Family

ID=26243566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BE2001/000017 WO2001057245A2 (en) 2000-02-04 2001-02-05 Hiv-1 resistance assay

Country Status (2)

Country Link
AU (1) AU2001233513A1 (en)
WO (1) WO2001057245A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009374D0 (en) * 2000-04-14 2000-05-31 Glaxo Group Ltd Phenotyping assay and reagents therefor
US7206699B2 (en) 2000-04-18 2007-04-17 Virco N.V. Methods for measuring therapy resistance
JP2004536594A (en) * 2001-06-04 2004-12-09 バイロロジック・インコーポレイテッド Compositions and methods for evaluating inhibitors of viral receptor / co-receptor availability and virus entry by recombinant virus assays
US7306901B2 (en) 2001-08-08 2007-12-11 Tibotec Pharmaceuticals, Ltd. Methods and means for assessing HIV envelope inhibitor therapy
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
EP1285971B1 (en) * 2001-08-08 2007-10-10 Tibotec Pharmaceuticals Ltd. Methods for the phenotypic and genotypic assessment of the drug sensitivity of HIV integrase variants
EP1446498B1 (en) 2001-11-08 2008-03-12 Tibotec Pharmaceuticals Ltd. Protease assay for therapeutic drug monitoring
US8790870B2 (en) 2006-02-03 2014-07-29 Virco Bvba Quantitative HIV phenotype or tropism assay

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011230A1 (en) * 1991-12-02 1993-06-10 Dynal As Modified mammalian stem cell blocking viral replication
EP0591914A2 (en) * 1992-10-06 1994-04-13 BEHRINGWERKE Aktiengesellschaft Retrovirus of the HIV-group and its application
US5427930A (en) * 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
US5599662A (en) * 1995-02-17 1997-02-04 Hoffmann-La Roche Inc. Oliconucleotide primers and probes for the detection of HIV-1
WO1997027480A1 (en) * 1996-01-26 1997-07-31 Virco N.V. Method of managing the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains
US5686272A (en) * 1992-05-29 1997-11-11 Abbott Laboratories Amplification of RNA sequences using the ligase chain reaction
WO1998051808A1 (en) * 1997-05-12 1998-11-19 Academisch Medisch Centrum Amsterdam Methods for producing retroviral vectors with an altered tropism

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427930A (en) * 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
WO1993011230A1 (en) * 1991-12-02 1993-06-10 Dynal As Modified mammalian stem cell blocking viral replication
US5686272A (en) * 1992-05-29 1997-11-11 Abbott Laboratories Amplification of RNA sequences using the ligase chain reaction
EP0591914A2 (en) * 1992-10-06 1994-04-13 BEHRINGWERKE Aktiengesellschaft Retrovirus of the HIV-group and its application
US5599662A (en) * 1995-02-17 1997-02-04 Hoffmann-La Roche Inc. Oliconucleotide primers and probes for the detection of HIV-1
WO1997027480A1 (en) * 1996-01-26 1997-07-31 Virco N.V. Method of managing the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains
WO1998051808A1 (en) * 1997-05-12 1998-11-19 Academisch Medisch Centrum Amsterdam Methods for producing retroviral vectors with an altered tropism

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ADACHI A ET AL: "PRODUCTION OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED RETROVIRUS IN HUMAN AND NONHUMAN CELLS TRANSFECTED WITH AN INFECTIOUS MOLECULAR CLONE", JOURNAL OF VIROLOGY, NEW YORK, US, US, vol. 59, no. 2, August 1986 (1986-08-01), pages 284 - 291, XP000870136, ISSN: 0022-538X *
CHO MICHAEL W ET AL: "Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4.", JOURNAL OF VIROLOGY, vol. 72, no. 3, March 1998 (1998-03-01), pages 2509 - 2515, XP002186429, ISSN: 0022-538X *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 25 November 1999 (1999-11-25), HUNG CHIA-SUEI ET AL: "Relationship between productive HIV-1 infection of macrophages and CCR5 utilization.", XP002186266, Database accession no. PREV200000104601 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; September 2000 (2000-09-01), PLUYMERS WIM ET AL: "Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters.", XP002186430, Database accession no. PREV200000461434 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; ESTE J A ET AL: "Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir).", XP002186265, retrieved from STN Database accession no. 1998130706 *
HERTOGS ET AL: "A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 42, no. 2, February 1998 (1998-02-01), pages 269 - 276, XP002137814, ISSN: 0066-4804 *
MARTINEZ-PICADO J ET AL: "HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 CLONING VECTORS FOR ANTIRETROVIRAL RESISTANCE TESTING", JOURNAL OF CLINICAL MICROBIOLOGY, WASHINGTON, DC, US, vol. 37, no. 9, September 1999 (1999-09-01), pages 2943 - 2951, XP002933597, ISSN: 0095-1137 *
MOLECULAR PHARMACOLOGY, (1998 FEB) 53 (2) 340-5. *
MOLECULAR PHARMACOLOGY, vol. 58, no. 3, September 2000 (2000-09-01), pages 641 - 648, ISSN: 0026-895X *
PANNECOUQUE C. ET AL.: "Viral entry as the primary target of anti-HIV activity of chicoric acid and its ttra-acetyl esters", ANTIVIRAL RESEARCH, vol. 46, no. 1, April 2000 (2000-04-01), pages A36, XP001038484 *
VIROLOGY, vol. 264, no. 2, 25 November 1999 (1999-11-25), pages 278 - 288, ISSN: 0042-6822 *

Also Published As

Publication number Publication date
AU2001233513A1 (en) 2001-08-14
WO2001057245A2 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
EP0887427A3 (en) Amplification and detection of hiv-1 and/or hiv-2
Trono Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses
WO2002072754A3 (en) Mva expressing modified hiv envelope, gag, and pol genes
WO2001044286A3 (en) Five-helix protein
WO2004087201A3 (en) Mva virus expressing modified hiv envelope, gag, and pol genes
CA2169315A1 (en) Primers and probes for the detection of hiv
EP2267452B8 (en) A soluble complex comprising a retroviral surface glycoprotein
WO1990015066A3 (en) Nucleotidic sequences resulting from the retrovirus gemone of the hiv-1, hiv-2, and siv type, and their applications, in particular for the amplification of the genomes of said retroviruses and for the in vitro diagnosis of infections caused by these viruses
AU8499901A (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
Papadopulos-Eleopulos et al. HIV & AIDS-The Isolation of HIV; Has it really been achieved? The case against
WO2001057245A3 (en) Hiv-1 resistance assay
MXPA02007478A (en) Human immunodeficiency virus vaccine.
McGrath et al. Using HIV-1 sequence variability to explore virus biology
WO2002038792A3 (en) Novel method for analysing phenotypic characteristics of human immunodeficiency virus (hiv)
Rodriguez et al. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)-and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections
IL122906A0 (en) Primers for the detection of hiv
WO2007018550A3 (en) Compositions and methods for the detection of hiv-1/hiv-2 infection
WO2004028473A3 (en) Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
Vogel et al. Self-limiting infection by int/nef-double mutants of simian immunodeficiency virus
TAN et al. Cotransfection of HIV-1 molecular clones with restricted cell tropism may yield progeny virus with altered phenotype
WO2003012148A3 (en) Molecular vector for the genophenotypic characterisation of v3 sequences of hiv-1 gp120
Sanchez-Palomino et al. Primary genetic characterization of HIV-1 isolates from WHO-sponsored vaccine evaluation sites by the RNase-A mismatch method
WO2003006065A3 (en) Pna conjugate for the treatment of diseases associated with hiv
Nandi UNINTEGRATED VIRAL, DNA AS A MARKER FOR HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION IN JTJO AND JN JITRO
WO2004093782A3 (en) Tumor cytotoxicity induced by modulators of the cxcr4 receptor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10211284

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP